Reference
Ai, X., Guo, X., Wang, J., Stancu, A. L., Joslin, P. M. N., Zhang, D., & Zhu, S. (2018). Targeted therapies for advanced non-small cell lung cancer. Oncotarget, 9 (101), 37589-37607. doi:10.18632/oncotarget.26428
Alfaro, C. L. (2001). Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacol Bull, 35 (4), 80-93.
Androutsopoulos, V. P., Spyrou, I., Ploumidis, A., Papalampros, A. E., Kyriakakis, M., Delakas, D., . . . Tsatsakis, A. M. (2013). Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS One, 8 (12), e82487. doi:10.1371/journal.pone.0082487
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., . . . Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol, 175 (7), 987-993. doi:10.1111/bph.14153
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer, 89 (3), 280-286. doi:10.1016/j.lungcan.2015.06.011
Filppula, A. M., Neuvonen, P. J., & Backman, J. T. (2014). In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos, 42 (7), 1202-1209. doi:10.1124/dmd.114.057695
Galetti, M., Petronini, P. G., Fumarola, C., Cretella, D., La Monica, S., Bonelli, M., . . . Alfieri, R. R. (2015a). Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLoS One, 10 (11), e0141795. doi:10.1371/journal.pone.0141795
Galetti, M., Petronini, P. G., Fumarola, C., Cretella, D., La Monica, S., Bonelli, M., . . . Alfieri, R. R. (2015b). Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. Plos One, 10 (11).
Huang, L., & Fu, L. (2015). Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B, 5 (5), 390-401. doi:10.1016/j.apsb.2015.07.001
Kazandjian, D., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016). FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clinical Cancer Research, 22 (6), 1307-1312.
Kitazaki, T., Oka, M., Nakamura, Y., Tsurutani, J., Doi, S., Yasunaga, M., . . . Kohno, S. (2005). Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer, 49 (3), 337-343. doi:10.1016/j.lungcan.2005.03.035
Li, X., Zhong, K., Guo, Z., Zhong, D., & Chen, X. (2015). Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. Drug Metab Dispos, 43 (11), 1751-1759. doi:10.1124/dmd.115.064121
Lu, J., Shang, X., Zhong, W., Xu, Y., Shi, R., & Wang, X. (2020). New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases.Acta Pharm Sin B, 10 (1), 91-104. doi:10.1016/j.apsb.2019.11.016
Malapelle, U., Muscarella, L. A., Pisapia, P., & Rossi, A. (2020). Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. Expert Opin Investig Drugs , 1-10. doi:10.1080/13543784.2020.1732922
Oyama, T., Sugio, K., Isse, T., Matsumoto, A., Nose, N., Uramoto, H., . . . Kawamoto, T. (2008). Expression of cytochrome P450 in non-small cell lung cancer. Front Biosci, 13 , 5787-5793.
Rahman, A. F., Korashy, H. M., & Kassem, M. G. (2014). Gefitinib. Profiles Drug Subst Excip Relat Methodol, 39 , 239-264. doi:10.1016/B978-0-12-800173-8.00005-2
Ranson, M., & Wardell, S. (2004). Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther, 29 (2), 95-103. doi:10.1111/j.1365-2710.2004.00543.x
Wahid, M., Mahjabeen, I., Baig, R. M., & Kayani, M. A. (2013). Expression of CYP1A1 and GSTP1 in human brain tumor tissues in Pakistan. Asian Pac J Cancer Prev, 14 (12), 7187-7191. doi:10.7314/apjcp.2013.14.12.7187
Wang., Y., & Jin, R. (2018). The research progress of c-Met inhibitors in clinical trials. Cancer Cell Research, 20 , 524-528.
Xi, N., Zhang, Y. J., Wang, Z. H., Wu, Y. J., & Wang, T. J. (2014). CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth.Cancer Research, 74 (19). doi:10.1158/1538-7445.Am2014-1755
Xia, P., Cao, J., Lv, X., Wang, L., Lv, W., & Hu, J. (2018). Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. Thorac Cancer, 9 (5), 656-661. doi:10.1111/1759-7714.12624
Zheng, W., Zhao, Y., Luo, Q., Zhang, Y., Wu, K., & Wang, F. Y. (2017). Multi-Targeted Anticancer Agents.Current Topics in Medicinal Chemistry, 17 (28), 3084-3098.